7/1/2010 12:39:04 PM - This high-ranked Medical - Generic Drugs industry firm is challenging its all-time highs this week, and no overhead supply remains to act as resistance. It rebounded with an impressive streak of gains with volume, rising from May - June lows after finding important support at its 200 DMA line. Recent quarters showed sales revenues increases gradually accelerating after a slight downturn. Earnings per share increases have been above the <strong>+25%</strong> guideline in <strong>3</strong> of the past <strong>4</strong> comparisons versus the year ago period. It has steady earnings history, but not a very strong annual earnings (<strong>A</strong> criteria) growth record. Leadership in the Medical - Generic Drugs group (<strong>L</strong> criteria) is very reassuring, while the weak market environment (<strong>M</strong> criteria) is an overriding concern.<br><hr>2/4/2010 12:32:01 PM - This high-ranked Medical - Generic Drugs industry firm is encountering distributional pressure and testing its 50 DMA line. That short-term average line provided support since it turned up from its low of <strong>$21.21</strong> and rallied sharply in March of 2009. Recent quarters showed sales revenues turning up after a slight downturn, while earnings per share increases have been above the <strong>+25%</strong> guideline in the <strong>2</strong> most recent comparisons versus the year ago period. It has steady earnings history, but not a very strong annual earnings (<strong>A</strong> criteria) record.<br><hr>2/1/2010 12:41:47 PM - This high-ranked Medical - Generic Drugs industry firm is consolidating above its 50 DMA line. That short-term average line provided support since it turned up from its low of <strong>$21.21</strong> and rallied sharply in March of 2009. Recent quarters showed sales revenues turning up after a slight downturn, while earnings per share increases have been above the <strong>+25%</strong> guideline in the <strong>2</strong> most recent comparisons versus the year ago period. It has steady earnings history, but not a very strong annual earnings (<strong>A</strong> criteria) record.<br><hr>1/25/2010 12:46:03 PM - This high-ranked Medical - Generic Drugs industry firm is near all-time highs and consolidating above its 50 DMA line.  That short-term average line provided support since it turned up from its low of <strong>$21.21</strong> and rallied sharply in March of 2009. Recent quarters showed sales revenues turning up after a slight downturn, while earnings per share increases have been above the <strong>+25%</strong> guideline in the <strong>2</strong> most recent comparisons versus the year ago period. It has steady earnings history, but not a very strong annual earnings (<strong>A</strong> criteria) record.<br><hr>10/28/2009 12:45:21 PM - Consolidating today after the high-ranked Medical - Generic Drugs industry firm traded above its 2006 all-time high on 10/27/09 and was noted with a gain backed by <strong>3</strong> times average volume. Recent quarters showed sales turning up after a slight downturn, and earnings per share increases have been above the <strong>+25%</strong> guideline in <strong>3</strong> of the past <strong>4</strong> comparisons versus the year ago period. It has steady earnings history, but not a very strong annual earnings (<strong>A</strong> criteria) record.<br><hr>10/27/2009 12:54:49 PM - The high-ranked Medical - Generic Drugs industry firm traded above its 2006 all-time high today with a gain backed by above average volume.  Recent quarters showed sales turning up after a slight downturn, and earnings per share increases have been above the <strong>+25%</strong> guideline in <strong>3</strong> of the past <strong>4</strong> comparisons versus the year ago period.  It has steady earnings history, but not a very strong annual earnings (<strong>A</strong> criteria) record.<br><hr>